Kumari Shalini
Research Subjects
Kumari Shalini has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Sushma Drabu
Maharaja Surajmal Institute of Pharmacy C-4, Janakpuri, New Delhi-58, India
2 shared publications - Nitin Kumar
Department of Pharmacy, Sushant School of Health Sciences, Ansal University, Gurugram, 122003, India
1 shared publication - Nitin Kumar
Department of Pharmaceutical Technology, Meerut Institute of Engineering & Technology, Meerut, U. P., India, Pin-250005
1 shared publication - Pramod Kumar Sharma
Department of Pharmaceutical Technology, Meerut Institute of Engineering & Technology, NH-58, Baghpat By-pass Crossing, Delhi-Haridwar Highway, Meerut-250005, India
1 shared publication
Latest Publications
- Open Access
- 1 February 2017
- Published by Scientific Scholar in Arabian Journal of Chemistry
- Vol. 10, S877-S880
Synthesis and pharmacological screening of 4, 6-substituted di-(phenyl) pyrimidin-2-amines
A new series of 4, 6-substituted di-(phenyl) pyrimidin-2-amine (IIa–d) were synthesized by reacting chalcone derivatives with guanidine hydrochloride in the presence of dimethylformamide. The synthesized compounds were characterized by spectral analysis and were screened for anti-inflammatory activity. Two compounds 4-(4-nitrophenyl)-6-phenylpyrimidine-2-amine (IIa) and 4-(4-methoxyphenyl)-6-phenylpyrimidine-2-amine (IIb) showed highly significant reduction in oedema volume
- 1 February 2017
- Published by Scientific Scholar in Arabian Journal of Chemistry
- Vol. 10, S877-S880
Open AccessSynthesis and pharmacological screening of 4, 6-substituted di-(phenyl) pyrimidin-2-amines
A new series of 4, 6-substituted di-(phenyl) pyrimidin-2-amine (IIa–d) were synthesized by reacting chalcone derivatives with guanidine hydrochloride in the presence of dimethylformamide. The synthesized compounds were characterized by spectral analysis and were screened for anti-inflammatory activity. Two compounds 4-(4-nitrophenyl)-6-phenylpyrimidine-2-amine (IIa) and 4-(4-methoxyphenyl)-6-phenylpyrimidine-2-amine (IIb) showed highly significant reduction in oedema volume
- Open Access
- 25 May 2011
- Published by Beilstein Institut in Beilstein Journal of Organic Chemistry
- Vol. 7 (1) , 668-677
Advances in synthetic approach to and antifungal activity of triazoles
Several five membered ring systems, e.g., triazole, oxadiazole dithiazole and thiadiazole with three heteroatoms at symmetrical or asymmetrical positions have been studied because of their interesting pharmacological properties. In this article our emphasis is on synthetic development and pharmacological activity of the triazole moiety which exhibit a broad spectrum of pharmacological activity such as antifungal, antibacterial, anti-inflammatory and anticancer etc. Triazoles have increased our ability to treat many fungal infections, for example, candidiasis, cryptococcal meningitis, aspergillosis etc. However, mortality due to these infections even with antifungal therapy is still unacceptably high. Therefore, the development of new antifungal agents targeting specific fungal structures or functions is being actively pursued. Rapid developments in molecular mycology have led to a concentrated search for more target antifungals. Although we are entering a new era of antifungal therapy in which we will continue to be challenged by systemic fungal diseases, the options for treatment will have greatly expanded.
- 25 May 2011
- Published by Beilstein Institut in Beilstein Journal of Organic Chemistry
- Vol. 7 (1) , 668-677
Open AccessAdvances in synthetic approach to and antifungal activity of triazoles
Several five membered ring systems, e.g., triazole, oxadiazole dithiazole and thiadiazole with three heteroatoms at symmetrical or asymmetrical positions have been studied because of their interesting pharmacological properties. In this article our emphasis is on synthetic development and pharmacological activity of the triazole moiety which exhibit a broad spectrum of pharmacological activity such as antifungal, antibacterial, anti-inflammatory and anticancer etc. Triazoles have increased our ability to treat many fungal infections, for example, candidiasis, cryptococcal meningitis, aspergillosis etc. However, mortality due to these infections even with antifungal therapy is still unacceptably high. Therefore, the development of new antifungal agents targeting specific fungal structures or functions is being actively pursued. Rapid developments in molecular mycology have led to a concentrated search for more target antifungals. Although we are entering a new era of antifungal therapy in which we will continue to be challenged by systemic fungal diseases, the options for treatment will have greatly expanded.